• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$84.90
+0 (0.00%)
Get New Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDCO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medicines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $84.90.

This chart shows the closing price for MDCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Medicines. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$78.00 ➝ $85.00Low
11/26/2019Chardan CapitalDowngradeBuy ➝ NeutralLow
11/25/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00Low
11/25/2019OppenheimerDowngradeOutperform ➝ Hold$68.00 ➝ $85.00High
11/25/2019Robert W. BairdDowngradeOutperform ➝ Neutral$100.00 ➝ $85.00Medium
11/25/2019CowenReiterated RatingBuy$60.00Low
11/20/2019CitigroupReiterated RatingHold$59.00High
11/19/2019Chardan CapitalReiterated RatingBuy$100.00Low
11/18/2019CowenReiterated RatingBuy$60.00High
10/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$44.00 ➝ $50.00High
10/2/2019B. RileyBoost TargetBuy$74.00 ➝ $95.00Low
9/17/2019CitigroupDowngradeBuy ➝ Neutral$55.00Low
9/3/2019Roth CapitalSet TargetBuy$72.00Low
9/3/2019SVB LeerinkReiterated RatingBuyLow
9/3/2019JPMorgan Chase & Co.Boost TargetOverweight$39.00 ➝ $49.00Medium
9/3/2019OppenheimerBoost TargetOutperform$52.00 ➝ $60.00High
9/3/2019CitigroupBoost TargetBuy ➝ Buy$48.00 ➝ $55.00High
9/2/2019Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$142.00 ➝ $145.00High
8/26/2019B. RileySet TargetBuy$61.00Low
8/26/2019Chardan CapitalSet TargetBuy$90.00Low
8/26/2019Roth CapitalSet TargetBuy$72.00Low
8/26/2019CowenSet TargetBuy$48.00Low
8/26/2019JPMorgan Chase & Co.Set TargetBuy$39.00Low
8/26/2019Bank of AmericaReiterated RatingBuy$51.00High
8/4/2019CowenSet TargetBuy$46.00Low
7/15/2019OppenheimerSet TargetBuy$48.00Low
7/9/2019Bank of AmericaReiterated RatingBuy ➝ Buy$36.00 ➝ $43.00Medium
5/28/2019B. RileySet TargetBuy$61.00Medium
5/20/2019B. RileySet TargetBuy$38.00Low
5/20/2019Robert W. BairdReiterated RatingOverweight$80.00 ➝ $110.00High
4/26/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00 ➝ $90.00High
4/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $55.00High
3/27/2019Robert W. BairdInitiated CoverageOutperform$80.00High
3/21/2019Roth CapitalInitiated CoverageBuy ➝ Buy$75.00 ➝ $75.00Low
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
12/13/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
11/11/2018CowenSet TargetBuy$46.00High
11/9/2018OppenheimerSet TargetBuy$50.00Low
9/24/2018OppenheimerSet TargetBuy$50.00High
8/20/2018CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $50.00Low
8/16/2018OppenheimerSet TargetBuy$50.00Low
6/7/2018B. RileyInitiated CoverageBuy$55.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/12/2018OppenheimerSet TargetBuy$50.00Low
2/23/2018Jefferies Financial GroupReiterated RatingBuy$47.00Low
2/22/2018OppenheimerSet TargetHold$50.00High
1/24/2018Chardan CapitalReiterated RatingBuy$85.00High
1/24/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$45.00High
1/22/2018CitigroupUpgradeNeutral ➝ Buy$40.00High
1/15/2018OppenheimerSet TargetBuy$50.00High
11/30/2017CitigroupUpgradeSell ➝ OutperformHigh
11/29/2017OppenheimerUpgradeMarket Perform ➝ Buy$50.00High
10/26/2017OppenheimerSet TargetHold$50.00N/A
10/26/2017Jefferies Financial GroupReiterated RatingBuy$54.00N/A
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/A
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
3/10/2022
  • 3 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
4/9/2022
  • 2 very positive mentions
  • 35 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
5/9/2022
  • 4 very positive mentions
  • 32 positive mentions
  • 6 negative mentions
  • 6 very negative mentions
6/8/2022
  • 3 very positive mentions
  • 32 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
7/8/2022
  • 4 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
8/7/2022
  • 5 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
9/6/2022
  • 0 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/6/2022

Current Sentiment

  • 0 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Medicines logo
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $84.90
Low: $84.90
High: $84.90

50 Day Range

MA: $84.90
Low: $84.90
High: $84.90

52 Week Range

Now: $84.90
Low: $17.81
High: $84.98

Volume

N/A

Average Volume

9,546,600 shs

Market Capitalization

$6.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicines?

The following Wall Street research analysts have issued stock ratings on Medicines in the last twelve months:
View the latest analyst ratings for MDCO.

What is the current price target for Medicines?

0 Wall Street analysts have set twelve-month price targets for Medicines in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medicines in the next year.
View the latest price targets for MDCO.

What is the current consensus analyst rating for Medicines?

Medicines currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDCO.

What other companies compete with Medicines?

How do I contact Medicines' investor relations team?

Medicines' physical mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company's listed phone number is 973-290-6000 and its investor relations email address is [email protected] The official website for Medicines is www.themedicinescompany.com. Learn More about contacing Medicines investor relations.